Hutch News
Results per Page:
Fred Hutch at ASCO: HPV vaccine uptake in U.S., immunotherapy and sarcoma, financial toxicity of cancer, health care disparities and more
The American Society of Clinical Oncology will hold its annual meeting May 31-June 4 in Chicago
Structural and clinical barriers keep 3 of 4 cancer patients from participating in trials
‘Patients are willing to participate in trials if they’re offered one’
Comorbidities impede clinical trial participation
From the Unger Group, Public Health Sciences Division
US cancer death rate has declined for at least 25 years
Fred Hutch experts weigh in on milestone report from American Cancer Society
How to boost cancer clinical trial participation
New study suggests loosening strict comorbidity criteria would open trials to thousands of previously exempt patients
Closing the rural-urban cancer survival gap
‘Guideline care’ in clinical trials erased cancer death-rate disparities
Prostate cancer risk: Medicare claims are a powerful link
From the Unger Group, Public Health Sciences Division
Acupuncture can curb AI-induced joint pain in some breast cancer patients
Large, randomized trial shows integrative approach relieves common side effect of estrogen-suppressing drug
Fred Hutch at ASCO
Immunotherapy advances, insights into health economics and leadership awards dominate oncology gathering
Cardiovascular disease competes with breast cancer
From the Unger Group, Public Health Sciences Division
Finasteride can reduce prostate cancer risk long term
Fred Hutch study taps big data to tease out extended cancer-prevention benefit of drug used for enlarged prostate, hair loss
Good News: Global Oncology wins NCI grant; 1100 Eastlake building honored; Bish Paul essay in Science; Dr. Joseph Unger leads finasteride study
Celebrating faculty and staff achievements
Cancer clinical trials: In defense of the negative result
Large cancer clinical trials that ‘fail’ carry just as much scientific oomph as positive findings, new study shows
Another health disparity: clinical trials
Low-income cancer patients are less likely to take part in clinical trials for new treatments, study shows